Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2023
|
| gptkbp:ATCCode |
L04AA56
|
| gptkbp:brand |
gptkb:Velsipity
gptkb:Etrasimod |
| gptkbp:CASNumber |
1204669-58-8
|
| gptkbp:chemicalFormula |
C26H24N2O3
|
| gptkbp:genericName |
gptkb:etrasimod
|
| https://www.w3.org/2000/01/rdf-schema#label |
Velsipity
|
| gptkbp:indication |
ulcerative colitis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
S1P receptor modulator
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
elevated liver enzymes nasopharyngitis |
| gptkbp:bfsParent |
gptkb:Etrasimod
|
| gptkbp:bfsLayer |
6
|